<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cefoxitin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cefoxitin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cefoxitin: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9223" href="/d/html/9223.html" rel="external">see "Cefoxitin: Drug information"</a> and <a class="drug drug_patient" data-topicid="11319" href="/d/html/11319.html" rel="external">see "Cefoxitin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list_set htclist drugH1Div drugBrandNames" id="F1046026"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Cephalosporin (Second Generation)</span></li></ul></div>
<div class="block don drugH1Div" id="F53462398"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-directed dosing: </i>Preterm and term neonates: IV: 90 to 100 mg/kg/day divided every 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6955661','lexi-content-ref-6653646','lexi-content-ref-Roos.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6955661','lexi-content-ref-6653646','lexi-content-ref-Roos.1'])">Ref</a></span>). <b>Note: </b>The youngest patient evaluated was 26 weeks GA.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Gestational age-directed dosing </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">GA &lt;32 weeks:</p>
<p style="text-indent:-2em;margin-left:8em;">PNA ≤7 days: IV, IM: 35 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">PNA &gt;7 days: IV, IM: 35 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">GA ≥32 weeks: IV, IM: 35 mg/kg/dose every 8 hours.</p></div>
<div class="block dop drugH1Div" id="F147699"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Infants, Children, and Adolescents: Limited data available in infants &lt;3 months of age: IM, IV: 80 to 160 mg/kg/day divided every 4 to 8 hours; maximum daily dose: 12 <b>g/day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.1','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.1','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="485d58ca-9e0e-4284-8228-d55fd4f946ff">Intra-abdominal infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intra-abdominal infection:</b>
<b>Note: </b>Cefoxitin is not recommended for the empiric treatment of intra-abdominal infection due to increasing resistance of anaerobic bacteria (ie, <i>Bacteroides fragilis </i>group); other options are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28085573'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available in infants &lt;3 months of age: IV: 80 to 160 mg/kg/day divided every 4 to 8 hours; maximum dose: 2,000 mg/dose. Use doses on the higher end of the range (ie, 160 mg/kg/day) for severe, complicated, or undrained infections (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3312564','lexi-content-ref-20034345','lexi-content-ref-28085573','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3312564','lexi-content-ref-20034345','lexi-content-ref-28085573','lexi-content-ref-manu.1'])">Ref</a></span>). Treatment duration should be 4 to 7 days unless source control inadequate; in some circumstances (ie, acute or gangrenous appendicitis without perforation) therapy should be limited to ≤24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20034345','lexi-content-ref-28085573']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20034345','lexi-content-ref-28085573'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8990a97-840a-4f1c-b589-4bb2832ec163">Mycobacterial infection, pulmonary infection in patients with or without cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial</b>
<b> (nontuberculous) infection (eg, <i>Mycobacterium abscessus</i>), pulmonary infection in patients with or without cystic fibrosis: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 12 <b>g/day</b>. The duration of parenteral therapy is generally 4 to 12 weeks depending on clinical response, followed by transition to oral and/or inhaled therapy; total antibiotic treatment duration is ≥12 months after culture conversion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29054853','lexi-content-ref-26678435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29054853','lexi-content-ref-26678435'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19ad33d2-38a3-4047-a6e2-816347270335">Pelvic inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥45 kg and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild to moderate (outpatient management):</i> IM: 2,000 mg as a single dose, in combination with a single dose of probenecid, followed by 14 days of oral therapy with doxycycline and metronidazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Severe (inpatient management): </i>IV: 2,000 mg every 6 hours in combination with doxycycline; once patient has clinically improved (typically within 24 to 48 hours), may transition to oral therapy with doxycycline and metronidazole to complete a total of 14 days of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd5111cb-cf78-4669-9c19-c01a1e98c57b">Peritonitis, prophylaxis in patients undergoing GI or genitourinary procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritonitis (peritoneal dialysis), prophylaxis in patients undergoing GI or genitourinary procedures:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: 30 to 40 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851742'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Limited data available in infants &lt;3 months of age: IV: 40 mg/kg within 60 minutes prior to surgery; may repeat dose in 2 hours for prolonged procedure or excessive blood loss; maximum dose: 2,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981','lexi-content-ref-AAP.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981','lexi-content-ref-AAP.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51084347"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Infants, Children, and Adolescents: The manufacturer's labeling suggests dosing modification consistent with the adult recommendations. Some clinicians have used the following guidelines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>); <b>Note:</b> Renally adjusted dose recommendations are based on doses of 20 to 40 mg/kg/dose every 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 8 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR 10 to 29 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;10 mL/minute/1.73 m<sup>2</sup>: 20 to 40 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent hemodialysis: Moderately dialyzable (20% to 50%): 20 to 40 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis (PD): 20 to 40 mg/kg/dose every 24 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous renal replacement therapy (CRRT): 20 to 40 mg/kg/dose every 8 hours.</p></div>
<div class="block dohp drugH1Div" id="F51084348"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F147677"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9223" href="/d/html/9223.html" rel="external">see "Cefoxitin: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range: IV:</b> 1 to 2 g every 6 to 8 hours.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a431e4d5-7cdc-40e4-ab99-a34db186cec0">Bite wound</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound (animal) (off-label use): IV:</b> 1 g every 6 to 8 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="211497db-429c-4f08-a5f9-b2bc63113006">Gonococcal infection, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gonococcal infection, uncomplicated (infection of the cervix, rectum, or urethra) (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use cefoxitin only if ceftriaxone is unavailable given a lack of contemporary efficacy data (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 2 g as a single dose <b>plus</b> oral probenecid; give in combination with treatment for chlamydia if it has not been excluded (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>). When treatment failure is suspected (eg, detection of <i>N. gonorrhoeae</i> after treatment without additional sexual exposure), consult an infectious diseases specialist. Report failures to the CDC through state and local health departments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c3c1ffc1-3b2c-44e1-abea-6af15373b052">Mycobacterial infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mycobacterial (nontuberculous, rapidly growing) infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients without cystic fibrosis: </i>2 to 4 g two to three times daily <b>or</b> 200 mg/kg/day in 3 divided doses (maximum daily dosage: 12 g/day) as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-29054853']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-29054853'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Patients with cystic fibrosis:</i> 200 mg/kg/day in 3 divided doses (maximum daily dosage: 12 g/day) as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26678435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26678435'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Duration of therapy:</i> The optimal duration of therapy is unknown, but generally the duration of parenteral therapy is ≤12 weeks depending on severity of infection, tolerability, and other patient-specific factors, followed by long-term oral maintenance therapy; consult an infectious diseases specialist for specific recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32797222','lexi-content-ref-29054853','lexi-content-ref-26678435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32797222','lexi-content-ref-29054853','lexi-content-ref-26678435'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="19ad33d2-38a3-4047-a6e2-816347270335">Pelvic inflammatory disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pelvic inflammatory disease: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inpatients:</i>
<b> IV:</b> 2 g every 6 hours in combination with doxycycline. Total duration of therapy (which may include oral step-down therapy) is 14 days; oral therapy can usually be initiated within 24 to 48 hours of clinical improvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Outpatients:</i>
<b> IM:</b> 2 g as a single dose <b>plus</b> oral probenecid, followed by oral doxycycline and metronidazole for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fa7b6aef-11c5-4b72-97a0-a39f0f808184">Surgical prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical (perioperative) prophylaxis: </b>
<b> IV:</b> 2 g within 60 minutes prior to surgical incision. Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23327981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23327981'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991792"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Single doses of IV or IM cefoxitin (eg, used for perioperative prophylaxis or outpatient treatment of pelvic inflammatory disease) do not require dosage adjustment for any degree of kidney dysfunction or in patients receiving kidney replacement therapies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:2em;">
<caption style="text-align:left;">
<b>Cefoxitin Dose Adjustments for Altered Kidney Function: IV<sup>a</sup></b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">CrCl</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>If the usual recommended dose is 1 to 2 g every 8 hours</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">If the usual recommended dose is 1 to 2 g every 6 hours</p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">If the usual recommended dose is 200 mg/kg per day in 3 divided doses (maximum 12 g/day)<sup>b</sup></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a </sup>Humbert 1979; expert opinion; manufacturer's labeling.</p></td></tr>
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>b </sup>No data available. Recommendations based on expert opinion only.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl &gt;50 mL/minute</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">No dosage adjustment necessary</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl 30 to 50 mL/minute</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 2 g every 12 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 2 g every 8 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">150 mg/kg per day in 3 divided doses (maximum 9 g per day)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl 10 to 29 mL/minute</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 2 g every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 to 2 g every 12 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">100 mg/kg per day in 2 divided doses (maximum 6 g per day)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">CrCl &lt;10 mL/minute</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 g once, followed by 500 mg to 1 g every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1 g every 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">50 mg/kg per day in 1 or 2 divided doses (maximum 3 g per day)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (&lt;55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29441476','lexi-content-ref-20000886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29441476','lexi-content-ref-20000886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Limited data for use of cefoxitin in ARC exist. For treatment of severe infections, consider alternative antimicrobial agents as the maximum daily dose (12 g per day) may still not achieve pharmacodynamic targets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36175707','lexi-content-ref-37796958','lexi-content-ref-37463564','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36175707','lexi-content-ref-37796958','lexi-content-ref-37463564','lexi-content-ref-Expert.DOR'])">Ref</a></span>). If necessary, consider 2 g every 4 hours. Prolonged (continuous or extended) infusions may be necessary to optimize PK/PD target attainment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36175707','lexi-content-ref-37796958','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36175707','lexi-content-ref-37796958','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Substantially dialyzable (exact % unknown) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-489205','lexi-content-ref-318213']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-489205','lexi-content-ref-318213'])">Ref</a></span>): <b>IV:</b> Dose as for CrCl &lt;10 mL/minute. When scheduled dose falls on a hemodialysis day, administer after dialysis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzable: <b>IV:</b> Dose as for CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4007038','lexi-content-ref-7347560','lexi-content-ref-6869373','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4007038','lexi-content-ref-7347560','lexi-content-ref-6869373','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Limited data exist for the use of cefoxitin in CRRT. Consider alternative antibiotic with more robust data for use. If necessary, dose as for CrCl 30 to 50 mL/minute.(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Limited data exist for use of cefoxitin in PIRRT. Consider alternative antibiotic with more robust data for use.</p>
<p style="text-indent:-2em;margin-left:6em;">If necessary:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>PIRRT days:</i> Dose as for CrCl 10 to 29 mL/minute, with one of the doses administered after the PIRRT session finishes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Non-PIRRT days:</i> Dose as for CrCl &lt;10 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988981"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F147643"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">1% to 10%: Gastrointestinal: Diarrhea </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">&lt;1%: Anaphylaxis, angioedema, bone marrow depression, dyspnea, eosinophilia, exacerbation of myasthenia gravis, exfoliative dermatitis, fever, hemolytic anemia, hypotension, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, interstitial nephritis, jaundice, leukopenia, nausea, nephrotoxicity (increased; with aminoglycosides), phlebitis, prolonged prothrombin time, pruritus, pseudomembranous colitis, skin rash, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, urticaria, vomiting</p></div>
<div class="block coi drugH1Div" id="F147659"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to cefoxitin, any component of the formulation, or other cephalosporins</p></div>
<div class="block war drugH1Div" id="F147640"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria). If a hypersensitivity reaction occurs, discontinue immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• GI disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Children: In pediatric patients ≥3 months of age, higher doses have been associated with an increased incidence of eosinophilia and elevated AST.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are more likely to have decreased renal function; use care in dose selection and monitor renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: For group A beta-hemolytic streptococcal infections, antimicrobial therapy should be given for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis.</p></div>
<div class="block foc drugH1Div" id="F147652"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p></div>
<div class="block geq drugH1Div" id="F147636"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323049"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (cefOXitin Sodium Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $3.60 - $11.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $7.20 - $23.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 g (per each): $60.00 - $112.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (cefOXitin Sodium-Dextrose Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM 4%(50ML) (per each): $22.63</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2GM 2.2%(50ML) (per each): $40.25</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866245"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 g (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 g (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52612383"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IV Push: Administer over 3 to 5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent IV infusion: Administer over 15 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3233896','lexi-content-ref-485129','lexi-content-ref-6653646','lexi-content-ref-7015265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3233896','lexi-content-ref-485129','lexi-content-ref-6653646','lexi-content-ref-7015265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">IM: Inject into a large muscle mass (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7387820','lexi-content-ref-3915286','lexi-content-ref-590313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7387820','lexi-content-ref-3915286','lexi-content-ref-590313'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F147656"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IM: Inject deep IM into large muscle mass. <b>Note:</b> IM injection is painful and this route of administration is not described in the prescribing information.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Can be administered IVP over 3 to 5 minutes or by IV intermittent infusion over 10 to 60 minutes</p></div>
<div class="block sts drugH1Div" id="F147668"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to reconstitution store between 2°C and 25°C (36°F and 77°F). Avoid exposure to temperatures &gt;50°C (122°F). Cefoxitin tends to darken depending on storage conditions; however, product potency is not adversely affected.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Reconstituted solutions of 1 g per 10 mL in sterile water for injection, bacteriostatic water for injection, sodium chloride 0.9% injection, or dextrose 5% injection are stable for 6 hours at room temperature or for 7 days under refrigeration (&lt;5°C [43°F]).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">DUPLEX container: Store unactivated container at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F); do not freeze. Following activation, solution is stable for 12 hours at room temperature and 7 days refrigerated.</p></div>
<div class="block usep drugH1Div" id="F53565936"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of the following susceptible bacterial infections: Lower respiratory tract, skin and soft tissue, bone and joint, urinary tract, gynecologic, and intra-abdominal infections; bacteremia/sepsis; surgical prophylaxis (All indications: FDA approved in ages ≥3 months and adults); has also been used for treatment of nontuberculous mycobacterial infections and in the prophylaxis of peritonitis in patients with peritoneal catheters undergoing GI or genitourinary procedures.</p></div>
<div class="block mst drugH1Div" id="F147726"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">CefOXitin may be confused with ceFAZolin, cefotaxime, cefoTEtan, cefTAZidime, cefTRIAXone, Cytoxan </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mefoxin may be confused with Lanoxin</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298992"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F147645"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F147662"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F5953484"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cefoxitin crosses the placenta and reaches the cord serum and amniotic fluid.</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of major birth defects or other adverse fetal or maternal outcomes has generally not been observed following use of cephalosporin antibiotics, including cefoxitin, during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Cefoxitin is one of the antibiotics recommended for prophylactic use prior to cesarean delivery (ACOG 199 2018).</p></div>
<div class="block mopp drugH1Div" id="F53565934"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function; CBC and LFTs (with prolonged use); prothrombin time (in patients at risk of bleeding or as clinically appropriate); number and type of stools/day for diarrhea. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>
<div class="block pha drugH1Div" id="F147639"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>
<div class="block phk drugH1Div" id="F147658"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely to body tissues and fluids including ascitic, pleural, synovial, bile; poorly penetrates into CSF even with inflammation of the meninges (Landesman 1981).</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates and Infants &lt;2 months of age (PNA: 10 to 53 days): 0.5 ± 0.21 L/kg (Regazzi 1983).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 65% to 79%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates and Infants &lt;2 months of age (PNA: 10 to 53 days): 1.4 hours (Regazzi 1983).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥3 months of age and Children: 42.4 ± 5.3 minutes (Feldman 1980).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 41 to 59 minutes; prolonged with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: IM: Within 20 to 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (85% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F58137684"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Time dependent; associated with time free drug concentration (<i>f</i>T) &gt; minimum inhibitory concentration (MIC): Goal: ≥40% to 50% (<i>f</i>T) &gt; MIC (bacteriostatic), ≥60% to 70% (<i>f</i>T) &gt; MIC (bactericidal) (Abdul-Aziz 2020; Craig 1996; Craig 1998; Turnidge 1998).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in normal renal function:</p>
<p style="text-indent:-2em;margin-left:8em;">Pediatric patients: C<sub>max </sub>(peak):</p>
<p style="text-indent:-2em;margin-left:10em;">Single dose (30 mg/kg): IV: Neonates and Infants &lt;2 months of age (PNA: 10 to 53 days): 69.8 ± 31.9 mg/L (Regazzi 1983).</p>
<p style="text-indent:-2em;margin-left:10em;">Steady state (37.5 mg/kg/dose every 6 hours): IV: Infants ≥3 months and Children: 81.9 ± 33 mg/L (Feldman 1980).</p>
<p style="text-indent:-2em;margin-left:8em;">Adults: C<sub>max </sub>(peak): Single dose (2 g): IV: 118.9 to 158.6 mg/L (Carver 1989; Isla 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect: </i>Generally &lt;1 hour; varies by organism (Craig 1991; Craig 1998). For <i>Bacteroides</i> spp.: Variable, ranging from 0 to 15 hours (Aldridge 2002; Siverhus 1988).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038555"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Foxitin | Mefoxin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cefoxitima richet | Cefoxitina fabra | Cefoxona | Mefoxin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cefoxitin | Mefoxitin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cefoxitin | Mefoxin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cefoxit | Cefoxitina sodica | Cefton | Foxtil | Kefox | Mefoxin | Propoten</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Cefoxitin | Da li ding | Fa ke | Fa li ke | Mefoxin | Pai qi xin | Pai qin | Wei Bo Xin | Yi fu xin | Yue le xin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cefoxin | Mefoxitin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cefoxitina | Cefoxitina ldp laboratorios torlan | Cefoxitina normon | Mefoxin | Mefoxitin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Plucefox</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cefaxicina | Cefoxitina Ips | Cefoxitina ldp laboratorios torlan | Cefoxitina normon | Mefoxitin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cefoxitine hospira | Cefoxitine panpharma | Mefoxin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin | Renoxitin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Destrepen | Mefoxil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Foxitin | Mefoxin | Voxitin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Cenomycin | Merxin banyu | Merxin torii | Taimetacin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cefoxitin | Cetazin | Jeitin | Pacetin | Shinpoong cefoxitin sodium | Union cefoxitin | Yooyoung cefoxitine sodium</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin | Tarcefoxin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Mefoxitin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cefoxitin actavis</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acifox | Alfoxin | Cefovex | Cefoxivit | Dintaxin | Foxitin | Geoxin | Haxotin | Mefoxin | Monowel | Onexitine | Oximed | Pacetin | Panafox | Xifox | Xitin | Zengram | Zepax</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin | Mefoxitin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cefoxitin | Mefoxin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Atralxitina | Cefoxitina | Cefoxitina basi | Cefoxitina hikma | Mefoxin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Ambicef | Anaerocef | Cefoxitin | Mefoxin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Foxitin | Mefoxin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cefoxin | Cefxitin | Maxotin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cefmore | Cefoxitin | Cexitin | Kinfotin | Lefoxin | Lephocin | Lifoxitin | Lofatin | Mefoxin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Mefoxitin</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Tenafotin 2000</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Mefoxin | Pharmacare-cefoxitin | Sabax cefoxitin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32383061">
<a name="32383061"></a>Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. <i>Intensive Care Med</i>. 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/32383061/pubmed" id="32383061" target="_blank">32383061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Abramowicz.1">
<a name="Abramowicz.1"></a>Abramowicz M, “Antimicrobial Prophylaxis in Surgery,” <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>, 16th ed, New York, NY: Medical Letter, 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16887672">
<a name="16887672"></a>Aldridge KE. Comparison of the post-antibiotic effect (PAE) induced by ceftizoxime, ceftriaxone, cefoxitin, ampicillin-sulbactam, and ticarcillin-clavulanate against selected isolates of Bacteroides fragilis and B. thetaiotaomicron. <i>Anaerobe</i>. 2002;8(6):295-299. doi:10.1016/S1075-9964(03)00024-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/16887672/pubmed" id="16887672" target="_blank">16887672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.1">
<a name="AAP.1"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30134425">
<a name="30134425"></a>American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin no. 199: Use of prophylactic antibiotics in labor and delivery [published correction appears in <i>Obstet Gynecol</i>. 2019;134(4):883-884]. <i>Obstet Gynecol</i>. 2018;132(3):e103‐e119. doi:10.1097/AOG.0000000000002833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/30134425/pubmed" id="30134425" target="_blank">30134425</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4007038">
<a name="4007038"></a>Arvidsson A, Alván G, Tranaeus A, Malmborg AS. Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis. <i>Eur J Clin Pharmacol</i>. 1985;28(3):333-337. doi:10.1007/BF00543333<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/4007038/pubmed" id="4007038" target="_blank">4007038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29441476">
<a name="29441476"></a>Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. <i>Clin Pharmacokinet</i>. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/29441476/pubmed" id="29441476" target="_blank">29441476</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23327981">
<a name="23327981"></a>Bratzler DW, Dellinger EP, Olsen KM, et al, “Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,” <i>Am J Health Syst Pharm</i>, 2013, 70(3):195-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/23327981/pubmed" id="23327981" target="_blank">23327981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8371696">
<a name="8371696"></a>“Antimicrobial Prophylaxis in Surgery,” <i>Med Lett Drugs Ther</i>, 1993, 35(906):91-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/8371696/pubmed" id="8371696" target="_blank">8371696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15227616">
<a name="15227616"></a>Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al, “Antimicrobial Prophylaxis for Surgery: An Advisory Statement From the National Surgical Infection Prevention Project,” <i>Clin Infect Dis</i>, 2004, 38(12):1706-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/15227616/pubmed" id="15227616" target="_blank">15227616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7387820">
<a name="7387820"></a>Buchanan N, Mithal Y, Witcomb M. Cefoxitin: intravenous pharmacokinetics and intramuscular bioavailability in kwashiorkor. <i>Br J Clin Pharmacol</i>. 1980;9(6):623-627. doi:10.1111/j.1365-2125.1980.tb01093.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/7387820/pubmed" id="7387820" target="_blank">7387820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2745258">
<a name="2745258"></a>Carver PL, Nightingale CH, Quintiliani R. Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. <i>J Antimicrob Chemother.</i> 1989;23(1):99-106. doi:10.1093/jac/23.1.99<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/2745258/pubmed" id="2745258" target="_blank">2745258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefoxitin.1">
<a name="Cefoxitin.1"></a>Cefoxitin injection, USP [prescribing information]. Lake Zurich, IL: Fresenius Kabi; May 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefoxitin.1">
<a name="Cefoxitin.1"></a>Cefoxitin injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cefoxitin.2">
<a name="Cefoxitin.2"></a>Cefoxitin injection pharmacy bulk package [prescribing information]. Eatontown, NJ: West-Ward; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36175707">
<a name="36175707"></a>Chabert P, Provoost J, Cohen S, et al. Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study. <i>Ann Intensive Care</i>. 2022;12(1):90. doi:10.1186/s13613-022-01059-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/36175707/pubmed" id="36175707" target="_blank">36175707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9455502">
<a name="9455502"></a>Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.<i> Clin Infect Dis</i>. 1998;26(1):1-10; quiz 11-12. doi:10.1086/516284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/9455502/pubmed" id="9455502" target="_blank">9455502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craig.1">
<a name="Craig.1"></a>Craig WA. The postantibiotic effect. <i>Clin Microbiology Newsletter.</i> 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8852915">
<a name="8852915"></a>Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. <i>Pediatr Infect Dis J</i>. 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/8852915/pubmed" id="8852915" target="_blank">8852915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32797222">
<a name="32797222"></a>Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. <i>Clin Infect Dis</i>. 2020;71(4):905-913. doi:10.1093/cid/ciaa1125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/32797222/pubmed" id="32797222" target="_blank">32797222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3277054">
<a name="3277054"></a>Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” <i>N Engl J Med</i>, 1988, 318(7):419-26 and 318(8):490-500.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/3277054/pubmed" id="3277054" target="_blank">3277054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6955661">
<a name="6955661"></a>Farmer K. Use of cefoxitin in the newborn. <i>N Z Med J</i>. 1982;95(709):398.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/6955661/pubmed" id="6955661" target="_blank">6955661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7396456">
<a name="7396456"></a>Feldman WE, Moffitt S, Sprow N. Clinical and pharmacokinetic evaluation of parental cefoxitin in infants and children. <i>Antimicrob Agents Chemother.</i> 1980;17(4):669-674. doi:10.1128/AAC.17.4.669<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/7396456/pubmed" id="7396456" target="_blank">7396456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26678435">
<a name="26678435"></a>Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. <i>Thorax</i>. 2016;71(1):88-90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/26678435/pubmed" id="26678435" target="_blank">26678435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-489205">
<a name="489205"></a>Garcia MJ, Dominguez-Gil A, Tabernero JM, Bondia Román A. Pharmacokinetics of cefoxitin in patients undergoing hemodialysis. <i>Int J Clin Pharmacol Biopharm</i>. 1979;17(8):366-370.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/489205/pubmed" id="489205" target="_blank">489205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7203727">
<a name="7203727"></a>Garcia MJ, Garcia A, Nieto MJ, et al, “Disposition of Cefoxitin in the Elderly,” <i>Int J Clin Pharmacol Ther Toxicol</i>, 1980, 18(11):503-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/7203727/pubmed" id="7203727" target="_blank">7203727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3233896">
<a name="3233896"></a>Garrelts JC, Ast D, LaRocca J, Smith DF Jr, Peterie JD. Postinfusion phlebitis after intravenous push versus intravenous piggyback administration of antimicrobial agents. <i>Clin Pharm</i>. 1988;7(10):760-765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/3233896/pubmed" id="3233896" target="_blank">3233896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37796958">
<a name="37796958"></a>Goutelle S, Jullien V, Bru JP, et al. Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study. <i>J Antimicrob Chemother</i>. 2023;78(11):2762-2769. doi:10.1093/jac/dkad300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/37796958/pubmed" id="37796958" target="_blank">37796958</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7347560">
<a name="7347560"></a>Greaves WL, Kreeft JH, Ogilvie RI, Richards GK. Cefoxitin disposition during peritoneal dialysis. <i>Antimicrob Agents Chemother</i>. 1981;19(2):253-255. doi:10.1128/AAC.19.2.253<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/7347560/pubmed" id="7347560" target="_blank">7347560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3312564">
<a name="3312564"></a>Gutiérrez C, Vila J, Garcia-Sala C, et al. Study of appendicitis in children treated with four different antibiotic regimens. <i>J Pediatr Surg</i>. 1987;22(9):865-868. doi:10.1016/s0022-3468(87)80657-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/3312564/pubmed" id="3312564" target="_blank">3312564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29054853">
<a name="29054853"></a>Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). <i>Thorax</i>. 2017;72(suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/29054853/pubmed" id="29054853" target="_blank">29054853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-318213">
<a name="318213"></a>Humbert G, Fillastre JP, Leroy A, Godin M, Van Winzum C. Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency. <i>Rev Infect Dis</i>. 1979;1(1):118-126. doi:10.1093/clinids/1.1.118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/318213/pubmed" id="318213" target="_blank">318213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22246211">
<a name="22246211"></a>Isla A, Trocóniz IF, de Tejada IL, et al. Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. <i>Eur J Clin Pharmacol.</i> 2012;68(5):735-745. doi:10.1007/s00228-011-1206-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/22246211/pubmed" id="22246211" target="_blank">22246211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women [published correction appears in <i>N Engl J Med.</i> 2000;343(18):1348]. <i>N Engl J Med</i>. 2000;343(2):118‐126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-485129">
<a name="485129"></a>Jacobson JA, Santos JI, Palmer WM. Clinical and bacteriological evaluation of cefoxitin therapy in children. <i>Antimicrob Agents Chemother</i>. 1979;16(2):183-185. doi:10.1128/AAC.16.2.183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/485129/pubmed" id="485129" target="_blank">485129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6269429">
<a name="6269429"></a>Landesman SH, Corrado ML, Shah PM, Armengaud M, Barza M, Cherubin CE. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis. <i>Am J Med</i>. 1981;71(4):693-703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/6269429/pubmed" id="6269429" target="_blank">6269429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al, "2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections," <i>Clin Infect Dis</i>, 2012, 54(12):e132-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10069359">
<a name="10069359"></a>Marshall WF and Blair JE, “The Cephalosporins,” <i>Mayo Clin Proc</i>, 1999, 74(2):187-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/10069359/pubmed" id="10069359" target="_blank">10069359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-400934">
<a name="400934"></a>McCloskey RV. Intramuscular cefoxitin. <i>Rev Infect Dis</i>. 1979;1(1):224-227.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/400934/pubmed" id="400934" target="_blank">400934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28085573">
<a name="28085573"></a>Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. <i>Surg Infect (Larchmt)</i>. 2017;18(1):1-76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/28085573/pubmed" id="28085573" target="_blank">28085573</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mefoxin.1">
<a name="Mefoxin.1"></a>Mefoxin (cefoxitin) [prescribing information]. Rockford, IL: Mylan Institutional LLC; February 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6653646">
<a name="6653646"></a>Regazzi MB, Chirico G, Cristiani D, Rondini G, Rondanelli R. Cefoxitin in newborn infants. A clinical and pharmacokinetic study. <i>Eur J Clin Pharmacol</i>. 1983;25(4):507-509. doi:10.1007/BF00542119<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/6653646/pubmed" id="6653646" target="_blank">6653646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3428165">
<a name="3428165"></a>Robinson DC, Cookson TL, Grisafe JA. Concentration guidelines for parenteral antibiotics in fluid-restricted patients. <i>Drug Intell Clin Pharm</i>. 1987;21(12):985-989. doi:10.1177/106002808702101212<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/3428165/pubmed" id="3428165" target="_blank">3428165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roos.1">
<a name="Roos.1"></a>Roos R, von Hattingberg HM, Belohradsky BH, et al. Pharmacokinetics of cefoxitin in premature and newborn infants studied by continuous serum level monitoring during combination therapy with penicillin and amikacin. <i>Infection</i>. 1980;8(6):301-306.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3915286">
<a name="3915286"></a>Rosaschino F, Vita CR, Bosco U, Castelli F, Vercelloni M. Clinical study with cefoxitin in paediatrics. <i>Drugs Exp Clin Res</i>. 1985;11(3):195-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/3915286/pubmed" id="3915286" target="_blank">3915286</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7015265">
<a name="7015265"></a>Santos JI, Jacobson JA, Swensen P, Palmer WM. Cellulitis: treatment with cefoxitin compared with multiple antibiotic therapy. <i>Pediatrics</i>. 1981;67(6):887-890.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/7015265/pubmed" id="7015265" target="_blank">7015265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3165611">
<a name="3165611"></a>Siverhus DJ, Edmiston CE Jr, Clausz JC, Goheen MP. Post-antibiotic effect in Bacteroides fragilis group. <i>Ann Clin Lab Sci</i>. 1988;18(4):326-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/3165611/pubmed" id="3165611" target="_blank">3165611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20034345">
<a name="20034345"></a>Solomkin JS, Mazuski JE, Bradley JS, et al, “Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,” <i>Clin Infect Dis</i>, 2010, 50(2):133-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/20034345/pubmed" id="20034345" target="_blank">20034345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-590313">
<a name="590313"></a>Sonneville PF, Albert KS, Skeggs H, Gentner H, Kwan KC, Martin CM. Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin. <i>Eur J Clin Pharmacol</i>. 1977;12(4):273-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/590313/pubmed" id="590313" target="_blank">590313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. <i>Clin Infect Dis</i>. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37463564">
<a name="37463564"></a>Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. <i>Clin Infect Dis</i>. Published online July 18, 2023. doi:10.1093/cid/ciad428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/37463564/pubmed" id="37463564" target="_blank">37463564</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9675443">
<a name="9675443"></a>Turnidge JD. The pharmacodynamics of beta-lactams. <i>Clin Infect Dis. 1998;27(1):10-22. doi:10.1086/514622</i>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/9675443/pubmed" id="9675443" target="_blank">9675443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6869373">
<a name="6869373"></a>Vlasses PH, D'Silva H, Rocci ML Jr, et al. Disposition of intravenous and intraperitoneal cefoxitin during chronic intermittent peritoneal dialysis. <i>Am J Kidney Dis</i>. 1983;3(1):67-70. doi:10.1016/s0272-6386(83)80013-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/6869373/pubmed" id="6869373" target="_blank">6869373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20000886">
<a name="20000886"></a>Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. <i>Clin Pharmacokinet</i>. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/20000886/pubmed" id="20000886" target="_blank">20000886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851742">
<a name="22851742"></a>Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;(32 Suppl 2):S32-S86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/22851742/pubmed" id="22851742" target="_blank">22851742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cefoxitin-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 13131 Version 229.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
